Anzeige
Mehr »
Sonntag, 07.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EGRS | ISIN: CA29842P1053 | Ticker-Symbol: X43
Frankfurt
05.09.25 | 08:44
4,460 Euro
-0,89 % -0,040
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
EUPRAXIA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
EUPRAXIA PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur EUPRAXIA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiShould you sell your Eupraxia Pharmaceuticals stock?1
MiEupraxia Pharmaceuticals Inc: Eupraxia releases first set of Resolve clinical results18
DiEUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer1
15.08.Is Eupraxia Pharmaceuticals a buy?1
13.08.Eupraxia Pharmaceuticals Inc: Eupraxia's June 30 cash balance at $19.8-million (U.S.)1
12.08.Eupraxia Pharmaceuticals reports Q2 results3
12.08.Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update148Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026Announced positive data from Phase 1b/2a RESOLVE supporting...
► Artikel lesen
22.07.EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer1
EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln
08.07.Eupraxia Pharmaceuticals Inc: Eupraxia doses first patient in phase 2b Resolve trial1
08.07.Stocks in Play: Eupraxia Pharmaceuticals Inc.-
08.07.Eupraxia Pharmaceuticals Inc.: Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis68Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study to a Phase 2b placebo-controlled study. This is a critical step required...
► Artikel lesen
08.07.EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer1
16.06.Canaccord Genuity initiates Eupraxia stock with spec. buy on EoE treatment2
03.06.Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders92VICTORIA, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging...
► Artikel lesen
07.05.Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 20251
07.05.Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results156Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to...
► Artikel lesen
05.05.Eupraxia Pharmaceuticals Inc: Eupraxia talks treatment outcomes in phase 1b/2a trial2
05.05.Stocks in Play: Eupraxia Pharmaceuticals Inc.-
05.05.EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer2
24.04.EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer1
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1